JP2009536956A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536956A5
JP2009536956A5 JP2009510180A JP2009510180A JP2009536956A5 JP 2009536956 A5 JP2009536956 A5 JP 2009536956A5 JP 2009510180 A JP2009510180 A JP 2009510180A JP 2009510180 A JP2009510180 A JP 2009510180A JP 2009536956 A5 JP2009536956 A5 JP 2009536956A5
Authority
JP
Japan
Prior art keywords
docetaxel
use according
dose
infusion time
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068727 external-priority patent/WO2007134203A2/en
Publication of JP2009536956A publication Critical patent/JP2009536956A/ja
Publication of JP2009536956A5 publication Critical patent/JP2009536956A5/ja
Pending legal-status Critical Current

Links

JP2009510180A 2006-05-12 2007-05-11 抗癌治療法 Pending JP2009536956A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80051006P 2006-05-12 2006-05-12
PCT/US2007/068727 WO2007134203A2 (en) 2006-05-12 2007-05-11 Anticancer treatments with a combination of docetaxel and ecteinascidin

Publications (2)

Publication Number Publication Date
JP2009536956A JP2009536956A (ja) 2009-10-22
JP2009536956A5 true JP2009536956A5 (enExample) 2010-05-27

Family

ID=38596836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510180A Pending JP2009536956A (ja) 2006-05-12 2007-05-11 抗癌治療法

Country Status (7)

Country Link
US (1) US20100009906A1 (enExample)
EP (1) EP2023931A2 (enExample)
JP (1) JP2009536956A (enExample)
AU (1) AU2007249281A1 (enExample)
CA (1) CA2652035A1 (enExample)
MX (1) MX2008014404A (enExample)
WO (1) WO2007134203A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Et−743およびパクリタキセルの使用を含むガンの併用療法
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
WO2002036125A1 (en) * 2000-10-31 2002-05-10 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy

Similar Documents

Publication Publication Date Title
Rejhová et al. Natural compounds and combination therapy in colorectal cancer treatment
JP2016528162A5 (enExample)
ES2622559T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
JP2009539769A5 (enExample)
JP2014512356A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
RU2016102158A (ru) Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
WO2004043389B1 (en) Methods of treating cancer and related methods
JP2020523356A5 (enExample)
JP2020523359A5 (enExample)
JP2009515901A5 (enExample)
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
RU2005141408A (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
JP2012522837A5 (enExample)
JP2002544231A5 (enExample)
CN103372210A (zh) 小檗碱联合化疗药物在抗肿瘤治疗中的应用
RU2004115110A (ru) Улучшенная схема применения противоопухолевого соединения в терапии рака
JP2014512355A5 (enExample)
JP2008517991A5 (enExample)
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2005049030A1 (en) Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
JP2020502182A5 (enExample)
RU2015139515A (ru) Комбинированное лечение